Abstract:A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or relapse after achieving remission. The latter arises from a few therapy-resistant cells within minimal residual disease (MRD). Resistant cells with long-term self-renewal capacity that drive clonal outgrowth are referred to as leukemic stem cells (LSC). The cancer stem cell concept considers LSC as relapse-initiating cells residing at the top of each genetically defined AML subclone forming epigenetically controlled downstream hierarchies. LSC display significant phenotypic and epigenetic plasticity, particularly in response to therapy stress, which results in various mechanisms mediating treatment resistance. Given the inherent chemotherapy resistance of LSC, targeted strategies must be incorporated into first-line regimens to prevent LSC-mediated AML relapse. The combination of venetoclax and azacitidine is a promising current strategy for the treatment of AML LSC. Nevertheless, the selection of patients who would benefit either from standard chemotherapy or venetoclax + azacitidine treatment in first-line therapy has yet to be established and the mechanisms of resistance still need to be discovered and overcome. Clinical trials are currently underway that investigate LSC susceptibility to first-line therapies. The era of single-cell multi-omics has begun to uncover the complex clonal and cellular architectures and associated biological networks. This should lead to a better understanding of the highly heterogeneous AML at the inter- and intra-patient level and identify resistance mechanisms by longitudinal analysis of patients' samples. This review discusses LSC biology and associated resistance mechanisms, potential therapeutic LSC vulnerabilities and current clinical trial activities.

Molecular Characteristics of Leukemia Stem Cells and Up-Dating Therapeutic Strategy

Research advancements in targeted elimination of leukemic stem cells

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

[Progress of Research on Leukemia Stem/progenitor Cell Targeting Therapy].

[Leukemia Stem/progenitor Cells and Target Therapy for Leukemia-- Review].

Targeting Acute Myeloid Leukemia Stem Cells: Current Therapies in Development and Potential Strategies with New Dimensions

Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells

Recent progress on targeting leukemia stem cells

The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting

Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells

Advances in Research of Leukemic Stem Cell

Concise Review: Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit.

Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development

[Research Progress in the Therapeutic Strategy Based on Targeting at Lung Cancer Stem Cell].

Drug Resistance of Tumor Stem Cells and Strategy of Therapy

Molecular Mechanisms for Stemness Maintenance of Acute Myeloid Leukemia Stem Cells

Leukemic stem cells and therapy resistance in acute myeloid leukemia

Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation

Cellular and Molecular State of Myeloid Leukemia Stem Cells.

[Lung Cancer Stem-like Cells and Drug Resistance].

Impaired Immunomodulatory Function of Chronic Myeloid Leukemia Cancer Stem Cells and the Possible Mechanism Involved in It